Literature DB >> 20876369

Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin.

Luis A Marcos1, Bernard C Camins.   

Abstract

Emerging infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) isolates are more likely to be associated with treatment failures than infections caused by other types of S. aureus. We present a case of pacemaker lead infective endocarditis caused by a non-daptomycin-susceptible strain of VISA. After 8 weeks of parenteral telavancin therapy, the patient achieved microbiological and clinical cure.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20876369      PMCID： PMC2981253          DOI： 10.1128/AAC.00857-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin.

Authors:  Heather Nace; Bennett Lorber
Journal:  J Antimicrob Chemother       Date:  2010-04-07       Impact factor: 5.790

2.  Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.

Authors:  Kathleen Julian; Klaudia Kosowska-Shick; Cynthia Whitener; Martin Roos; Harald Labischinski; Aileen Rubio; Leslie Parent; Lois Ednie; Laura Koeth; Tatiana Bogdanovich; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

3.  In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.

Authors:  Rodrigo E Mendes; Gary J Moet; Mike J Janechek; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

4.  Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.

Authors:  Andres G Madrigal; Li Basuino; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Ann F Bolger; Matthew E Levison; Patricia Ferrieri; Michael A Gerber; Lloyd Y Tani; Michael H Gewitz; David C Tong; James M Steckelberg; Robert S Baltimore; Stanford T Shulman; Jane C Burns; Donald A Falace; Jane W Newburger; Thomas J Pallasch; Masato Takahashi; Kathryn A Taubert
Journal:  Circulation       Date:  2005-06-14       Impact factor: 29.690

Review 6.  Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance.

Authors:  K Hiramatsu
Journal:  Lancet Infect Dis       Date:  2001-10       Impact factor: 25.071

Review 7.  New agents for Staphylococcus aureus endocarditis.

Authors:  Marci Drees; Helen Boucher
Journal:  Curr Opin Infect Dis       Date:  2006-12       Impact factor: 4.915

8.  Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.

Authors:  José M Miró; Cristina García-de-la-Mària; Yolanda Armero; Elisa de-Lazzari; Dolors Soy; Asunción Moreno; Ana del Rio; Manel Almela; Carlos A Mestres; José M Gatell; María-Teresa Jiménez-de-Anta; Francesc Marco
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

9.  Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance.

Authors:  In-Gyu Bae; Jerome J Federspiel; José M Miró; Christopher W Woods; Lawrence Park; Michael J Rybak; Thomas H Rude; Suzanne Bradley; Suzana Bukovski; Cristina Garcia de la Maria; Souha S Kanj; Tony M Korman; Francesc Marco; David R Murdoch; Patrick Plesiat; Marta Rodriguez-Creixems; Porl Reinbott; Lisa Steed; Pierre Tattevin; Marie-Françoise Tripodi; Karly L Newton; G Ralph Corey; Vance G Fowler
Journal:  J Infect Dis       Date:  2009-11-01       Impact factor: 5.226

Review 10.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132
  10 in total
  12 in total

Review 1.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

2.  In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.

Authors:  Abrar K Thabit; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

3.  Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.

Authors:  Rodrigo E Mendes; David J Farrell; Helio S Sader; Robert K Flamm; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

Review 4.  Once-Daily Treatments for Methicillin-Susceptible Staphylococcus aureus Bacteremia: Are They Good Enough?

Authors:  Sylvain A Lother; Natasha Press
Journal:  Curr Infect Dis Rep       Date:  2017-09-23       Impact factor: 3.725

5.  Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.

Authors:  Truc T Tran; Vincent H Tam; Barbara E Murray; Cesar A Arias; Kavindra V Singh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

Review 6.  Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature.

Authors:  Sanjiv M Baxi; Dominic Chan; Vivek Jain
Journal:  Infection       Date:  2015-03-25       Impact factor: 3.553

Review 7.  Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.

Authors:  Arnold S Bayer; Tanja Schneider; Hans-Georg Sahl
Journal:  Ann N Y Acad Sci       Date:  2012-12-05       Impact factor: 5.691

Review 8.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

Review 9.  Update on the emerging role of telavancin in hospital-acquired infections.

Authors:  Obinna N Nnedu; George A Pankey
Journal:  Ther Clin Risk Manag       Date:  2015-04-13       Impact factor: 2.423

10.  A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.

Authors:  Martin E Stryjewski; Arnold Lentnek; William O'Riordan; John Pullman; Paul Anantharajah Tambyah; Jose M Miró; Vance G Fowler; Steven L Barriere; Michael M Kitt; G Ralph Corey
Journal:  BMC Infect Dis       Date:  2014-05-23       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.